News | February 22, 2022
Daewoong Pharmaceutical posts strong financials in 2021
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The facility will manufacture its Herceptin biosimilar, Tuznue
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Subscribe To Our Newsletter & Stay Updated
